✦ LIBER ✦

Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin’s lymphoma

✍ Scribed by Hisashi Tsurumi; Toshiki Yamada; Michio Sawada; Senji Kasahara; Nobuhiro Kanemura; Yasushi Kojima; Kenji Fukuno; Takeshi Hara; Masanao Saio; Takeshi Takahashi; Masami Oyama; Keiya Ozawa; Tsuyoshi Takami; Hisataka Moriwaki

Book ID: 106123323
Publisher: Springer-Verlag
Year: 2004
Tongue: English
Weight: 225 KB
Volume: 130
Category: Article
ISSN: 1432-1335
DOI: 10.1007/s00432-003-0508-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Early cardiotoxicity of the CHOP regimen

Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma

✍ Limat, S. 📂 Article 📅 2003 🏛 Oxford University Press 🌐 English ⚖ 78 KB

Long-term Results of a Multicenter Rando

Long-term Results of a Multicenter Randomized, Comparative Trial of Modified CHOP versus THP-COP versus THP-COPE Regimens in Elderly Patients with Non-Hodgkin’s Lymphoma

✍ Mayumi Mori; Kiyoshi Kitamura; Michihiko Masuda; Tomomitsu Hotta; Tamotsu Miyaza 📂 Article 📅 2005 🏛 Carden Jennings Publishing 🌐 English ⚖ 161 KB

Phase I/II Trial of Nonpegylated Liposom

Phase I/II Trial of Nonpegylated Liposomal Doxorubicin, Cyclophosphamide, Vincristine, and Prednisone in the Treatment of Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma

✍ Tulpule, Anil; Espina, Byron M.; Berman, Nancy; Buchanan, Laura H.; Smith, D. Ly 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 131 KB

CHOP vs. ProMACE-CytaBOM in the treatmen

CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: long-term results of a multicenter randomized trial

✍ E. Montserrat; J. García-Conde; N. Viñolas; A. López-Guillermo; L. Hernández-Nie 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 533 KB

WITHDRAWN: Addition of amifostine to CHO

WITHDRAWN: Addition of amifostine to CHOP regimen significantly reduced toxicity in patients with aggressive non-Hodgkin’s lymphoma without affecting the long term survival: Results of a phase II trial

✍ Gómez, Henry L. 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 29 KB

Phase II study of cyclophosphamide, doxo

Phase II study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low- and low–intermediate risk, aggressive non-Hodgkin’s lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG9508

✍ Kagami, Yoshitoyo; Itoh, Kuniaki; Tobinai, Kensei; Fukuda, Haruhiko; Mukai, Kiyo 📂 Article 📅 2012 🏛 Carden Jennings Publishing 🌐 English ⚖ 308 KB